PL331465A1 - Novel compounds and agents for treating diseases associated with triptase activity - Google Patents

Novel compounds and agents for treating diseases associated with triptase activity

Info

Publication number
PL331465A1
PL331465A1 PL97331465A PL33146597A PL331465A1 PL 331465 A1 PL331465 A1 PL 331465A1 PL 97331465 A PL97331465 A PL 97331465A PL 33146597 A PL33146597 A PL 33146597A PL 331465 A1 PL331465 A1 PL 331465A1
Authority
PL
Poland
Prior art keywords
triptase
agents
activity
novel compounds
diseases associated
Prior art date
Application number
PL97331465A
Other languages
English (en)
Inventor
Jeffrey Mark Dener
Elaine Yee-Lin Kuo
Ken Duane Rice
Vivian Rueywen Wang
Wendy Beth Young
Original Assignee
Axys Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Axys Pharmaceuticals filed Critical Axys Pharmaceuticals
Publication of PL331465A1 publication Critical patent/PL331465A1/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/20Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/20Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
    • C07D295/215Radicals derived from nitrogen analogues of carbonic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/06Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms
    • C07D233/08Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms with alkyl radicals, containing more than four carbon atoms, directly attached to ring carbon atoms
    • C07D233/12Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms with alkyl radicals, containing more than four carbon atoms, directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D233/14Radicals substituted by oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
PL97331465A 1996-07-30 1997-07-30 Novel compounds and agents for treating diseases associated with triptase activity PL331465A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2313996P 1996-07-30 1996-07-30
US89577297A 1997-07-17 1997-07-17

Publications (1)

Publication Number Publication Date
PL331465A1 true PL331465A1 (en) 1999-07-19

Family

ID=26696778

Family Applications (1)

Application Number Title Priority Date Filing Date
PL97331465A PL331465A1 (en) 1996-07-30 1997-07-30 Novel compounds and agents for treating diseases associated with triptase activity

Country Status (17)

Country Link
EP (1) EP0934293A1 (fr)
JP (1) JP2001509787A (fr)
KR (1) KR20000029679A (fr)
CN (1) CN1073103C (fr)
AU (1) AU733621B2 (fr)
CA (1) CA2262542A1 (fr)
CZ (1) CZ29799A3 (fr)
EE (1) EE9900036A (fr)
FI (1) FI990171A (fr)
HU (1) HUP0003267A3 (fr)
LV (1) LV12291B (fr)
NO (1) NO990433L (fr)
NZ (1) NZ333713A (fr)
PL (1) PL331465A1 (fr)
SI (1) SI9720047A (fr)
SK (1) SK8599A3 (fr)
WO (1) WO1998004537A1 (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6221914B1 (en) 1997-11-10 2001-04-24 Array Biopharma Inc. Sulfonamide bridging compounds that inhibit tryptase activity
ES2233025T3 (es) * 1998-02-06 2005-06-01 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Agente inhibidores de la triptasa.
US6613769B1 (en) * 1998-02-06 2003-09-02 Max-Planck-Gesellschaft zur Föderung der Wissenschaften. e.V. Tryptase inhibitors
IL141654A0 (en) * 1998-09-04 2002-03-10 Byk Gulden Lomberg Chem Fab Pyranose derivatives and pharmaceutical compositions containing the same
ATE279398T1 (de) 1999-08-10 2004-10-15 Altana Pharma Ag Diazocindionderivate und ihre verwendung als tryptase inhibitoren
EP1216236A1 (fr) * 1999-09-14 2002-06-26 Byk Gulden Lomberg Chemische Fabrik GmbH Inhibiteurs de la tryptase
WO2001036386A1 (fr) * 1999-11-17 2001-05-25 Sumitomo Pharmaceuticals Co., Ltd. Traitement du diabete contenant un derive de dipiperazine
DE19955476A1 (de) * 1999-11-18 2001-05-23 Boehringer Ingelheim Pharma Bis-basische Verbindungen als Tryptase-Inhibitoren, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
WO2001046128A2 (fr) 1999-12-20 2001-06-28 Byk Gulden Lomberg Chemische Fabrik Gmbh Inhibiteurs de tryptase
SI1244643T1 (en) * 1999-12-20 2004-12-31 Altana Pharma Ag Tryptase inhibitors
US6924305B2 (en) 2001-01-31 2005-08-02 Altana Pharma Ag Diazocine derivatives and their use as tryptase inhibitors
WO2002066420A2 (fr) * 2001-02-21 2002-08-29 Altana Pharma Ag Inhibiteurs de la tryptase
DE60217076T2 (de) 2001-02-21 2007-06-21 Altana Pharma Ag Tryptaseinhibitoren
WO2002074732A2 (fr) * 2001-03-15 2002-09-26 Altana Pharma Ag Inhibiteurs de la tryptase
JP2004525926A (ja) * 2001-03-15 2004-08-26 アルタナ ファルマ アクチエンゲゼルシャフト トリプターゼ阻害剤
US7186855B2 (en) 2001-06-11 2007-03-06 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US6818787B2 (en) 2001-06-11 2004-11-16 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
IL159299A0 (en) 2001-06-11 2004-06-01 Xenoport Inc Orally administered dosage forms of gaba analog prodrugs having reduced toxicity
CA2450659A1 (fr) 2001-06-19 2002-12-27 Altana Pharma Ag Inhibiteurs de tryptase
AU2005301970B2 (en) 2004-11-04 2011-06-02 Arbor Pharmaceuticals, Llc Gabapentin prodrug sustained release oral dosage forms
US8399519B2 (en) * 2008-12-19 2013-03-19 Merz Pharma Gmbh & Co. Kgaa 1-amino-alkylcyclohexane derivatives for the treatment of mast cell mediated diseases
TWI432188B (zh) 2008-12-19 2014-04-01 Merz Pharma Gmbh & Co Kgaa 供治療發炎性皮膚疾病之1-胺基-烷基環己烷衍生物類
FR3038605B1 (fr) 2015-07-06 2018-08-24 Universite Amiens Picardie Jules Verne Diamines primaires vicinales associees a des motifs chelateurs de metaux et/ou de radicaux libres, actives contre les stress carbonyle et oxydant et leur utilisation
CN110869362A (zh) * 2017-05-12 2020-03-06 国立研究开发法人理化学研究所 A类gpcr结合性化合物改性体

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4845242A (en) * 1987-04-28 1989-07-04 Georgia Tech Research Corporation Isocoumarins with basic substituents as serine proteases inhibitors, anticoagulants and anti-inflammatory agents
EP0688337A1 (fr) * 1993-03-12 1995-12-27 Arris Pharmaceutical Corporation Compositions et procedes pour le traitement d'affections inflammatoires immunoresultantes
US5525623A (en) * 1993-03-12 1996-06-11 Arris Pharmaceutical Corporation Compositions and methods for the treatment of immunomediated inflammatory disorders
WO1995032945A1 (fr) * 1994-06-01 1995-12-07 Arris Pharmaceutical Corporation Compositions et procedes de traitement d'etats induits par des mastocytes
WO1996009297A1 (fr) * 1994-09-23 1996-03-28 Arris Pharmaceutical Corporation Compositions et procedes de traitement de maladies inflammatoires provoquees par les mastocytes
CZ298197A3 (cs) * 1995-03-24 1998-03-18 Arris Pharmaceutical Corporation Reverzibilní inhibitory proteas
TW438591B (en) * 1995-06-07 2001-06-07 Arris Pharm Corp Reversible cysteine protease inhibitors

Also Published As

Publication number Publication date
NZ333713A (en) 2000-12-22
EE9900036A (et) 1999-08-16
SI9720047A (sl) 1999-08-31
CA2262542A1 (fr) 1998-02-05
AU733621B2 (en) 2001-05-17
CN1226892A (zh) 1999-08-25
JP2001509787A (ja) 2001-07-24
FI990171A0 (fi) 1999-01-29
WO1998004537A1 (fr) 1998-02-05
LV12291B (en) 2000-04-20
CZ29799A3 (cs) 1999-06-16
CN1073103C (zh) 2001-10-17
FI990171A (fi) 1999-03-23
AU3967097A (en) 1998-02-20
HUP0003267A2 (hu) 2001-06-28
KR20000029679A (ko) 2000-05-25
NO990433L (no) 1999-03-25
LV12291A (lv) 1999-06-20
SK8599A3 (en) 2000-03-13
HUP0003267A3 (en) 2002-02-28
NO990433D0 (no) 1999-01-29
EP0934293A1 (fr) 1999-08-11

Similar Documents

Publication Publication Date Title
PL331465A1 (en) Novel compounds and agents for treating diseases associated with triptase activity
GB9417956D0 (en) Therapeutic agents
GB9415996D0 (en) Therapeutic agents
GB9418545D0 (en) Therapeutic agents
GB9417310D0 (en) Therapeutic agents
GB9416189D0 (en) Therapeutic agents
GB9416162D0 (en) Therapeutic agents
GB9402641D0 (en) Therapeutic agents
GB9410031D0 (en) Therapeutic agents
EP0921803A4 (fr) Procede permettant de prevenir et de traiter une infection pestivirale et les maladies qui y sont associees
GB9411955D0 (en) Therapeutic agents
GB9409264D0 (en) Therapeutic agents
GB9415575D0 (en) Therapeutic agents
GB9401879D0 (en) Therapeutic agents
GB9403639D0 (en) Therapeutic agents
LT99019A (en) Novel compounds and compositions for treating diseases associated with tryptase activity
GB9410080D0 (en) Therapeutic agents
GB9415576D0 (en) Therapeutic agents
GB9408963D0 (en) Therapeutic agents
GB9408458D0 (en) Therapeutic agents
GB9410027D0 (en) Therapeutic agents
GB9408160D0 (en) Therapeutic agents
GB9410074D0 (en) Therapeutic agents
GB9407236D0 (en) Therapeutic agents
GB9411953D0 (en) Therapeutic agents